Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28593180 | 0.83 | RIPK1 (0.55) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL23894979 | 0.82 | RIPK1 (0.50) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL1911377 | 0.82 | RIPK1 (0.50) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL13573943 | 0.81 | RIPK1 (0.53) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL7773795 | 0.81 | RIPK1 (0.53) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL8235389 | 0.81 | RIPK1 (0.53) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL8597350 | 0.80 | HRH1 (0.56) | TAAR1IDO1 | |
| SCHEMBL6280516 | 0.79 | RIPK1 (0.67) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL837630 | 0.79 | RIPK1 (0.52) | TAAR1RIPK1AOC3TRPA1 | |
| SCHEMBL13255813 | 0.79 | TAAR1 (0.48) | TAAR1RIPK1AOC3TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| CN-101107000-A | 3,6-bicyclolides | ENANTA PHARM INC (US) | 2008-01-16 | — | — | CN | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122128-A1 | 3,6-Bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122128-A1 | 3,6-Bicyclolides | ABCB11, CYP2B6, CYP3A7 | TAAR1 4777/4885RIPK1 2696/4885AOC3 2703/4885 |
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | TAAR1 4777/4885RIPK1 2696/4885AOC3 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.